,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['mbc', 'breast', 'destinybreast04']
#asco22 - #destinybreast04
we saw it coming, but it still swept us away.
re-testing her2 status on metastases in her2-negative mbc pts with an original her2-0 report is now of the utmost importance. 
Ricercatore Oncologia Medica